Tokalas Inc. on Monday announced the appointment of Dr. James B. Breitmeyer to the position of president and chief executive officer.
Breitmeyer, an oncologist, has over 25 years of experience in the pharmaceutical industry. He was most recently president of Bavarian Nordic Inc. and executive vice president of Bavarian Nordic A/S, where he was responsible for securing a $975 million immune-oncology commercialization partnership with Bristol-Myers Squibb.
Breitmeyer held executive leadership positions at Zogenix Inc., where he remains a director, Cadence Pharmaceuticals Inc. (acquired by Mallinkrodt), Applied Molecular Evolution (acquired by Eli Lilly and Co.), Serono Laboratories (acquired by Merck), and was the founding president and CEO of the Harvard Clinical Research Institute.
He has led efforts resulting in eight FDA and/or international product approvals including Zohydro, Ofirmev, Rebif, Saizen, Geref, Serostim, Fertinex, and Gonal-F.
Tokalas is a Del Mar-based biopharmaceutical company focused on the development and commercialization of a novel, first-in-class ets-family transcription factor inhibitor for the treatment of cancer. The Tokalas team has advanced its lead compound through preclinical development and will initiate clinical trials in Ewing Sarcoma in late 2015 early 2016.